The companies did not release details on which regions Boston Scientific would distribute the stent in or any financial terms of the deal.
“The Vici venous stent is widely recognized as state-of-the-art technology for venous stents and physicians routinely praise the product for its performance qualities. We are extremely pleased to be partnering with a global industry leader like Boston Scientific to advance the Vici Venous Stent in the marketplace. Boston Scientific’s market leadership and reach will provide more physicians treating patients suffering from venous outflow obstruction around the world greater access to leading-edge technology,” Veniti prez & CEO Jeff Elkins said in a press release.
The Vici stent, launched in 2014 by Fremont, Calif.-based Veniti, is designed to treat venous disorders and is available in a conventional delivery system.
Veniti said it is currently conducting a trial of the device exploring its use treating chronic iliofemoral venous outflow obstruction under and FDA investigational device exemption.
Last September, Boston Scientific put up $25 million for Veniti’s Series D round, with funds set to support its Virtus chronic iliofemoral venous outflow trial.